The paradigm shift from cytotoxic drugs to targeted treatments including small molecules, monoclonal antibodies and immune therapies necessitates a similar shake up in the regulation and funding of cancer biomarkers. According to a report from the University of South Australia’s Sansom Institute for Health Research, capitalising on the opportunities that come with targeted therapies has ...
Australia needs to play catch up on cancer biomarkers
By Mardi Chapman
30 Nov 2017